Last
Update:
January 02, 2011
Perinatal Journal Data are integrated with Perinatal Conference Data in
the Perinatal Data Page.
Pediatric Journal Data are integrated with Pediatric Conference Data in
the Pediatric Data Page
 Documents identified with this icon
are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader.
4th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
Delfraissy JF, Flandre P, Ngo Van P, et al
Abstract
No observable correlation between central nervous system side effects and
EFV plasma
concentrations in Japanese HIV-1 infected patients treated with EFV
containing HAART
Takahashi M, Ibe S, Kudaka Y, et al
Abstract
Similar antiviral efficacy and tolerability between efavirenz and
lopinavir/ritonavir
administered with abacavir/lamivudine (KIVEXA) in antiretroviral-naïve
patients: a multicentre,
randomized study (LAKE study)
Echeverria P, Alonso MM, Portilla J, et al
Abstract
D Kuritzkes, C Lalama, H Ribaudo, et al
Abstract
Plasma
Concentrations of Efavirenz and Lopinavir in Children with and without
Rifampicin-based
Anti-TB Treatment
Y Ren, J Nuttall, C Egbers, et al
Abstract
Drug
Interaction between Antimalarial Drugs and Efavirenz
P German, B Greenhouse, C Coates, et al
Abstract
POSTER
Pharmacokinetic Interaction between Efavirenz
and Diltiazem or Itraconazole after Multiple-dose
Administration in Adult Healthy Subjects
S Kaul, P Ji, J Dudley, et al
PDF Poster
Abstract
Efavirenz-
vs Nevirapine-based ART Regimens: Adherence and Virologic Outcomes
J Nachega, M Hislop, D Dowdy, et al
Abstract
Mechanism
of Synergy between Efavirenz and Zidovudine: Role of HIV-1 Reverse
Transcriptase
RNase H
Activity
J Radzio N Sluis-Cremer
Abstract
Brief
Exposure to Efavirenz Monotherapy Selects NNRTI-resistant Mutants and
Compromises
Virologic
Response to Tenofovir, Emtricitabine, and Efavirenz in a SHIV Model of ART
in Macaques
Z Ambrose, S Palmer, V Boltz, et al
Abstract
K101E, in
Combination with G190S, Confers Reduced Fitness and Efavirenz-dependent
Stimulation
of HIV
Replication that Are Influenced by Nucleoside Resistance Mutations and RT
Polymorphisms
J Wang, C Dykes, H Liang. et al
Abstract
POSTER
Pregnancy Outcomes of Women Receiving Efavirenz after the First Trimester
N Phanuphak, T Apornpong, S Limpongsanurak, et al
PDF Poster
Abstract
The
Assessment of Multi-locus Gene Effects upon Efavirenz Pharmacokinetics
T Mahungu, S Khoo, C Smith, et al
Abstract
8th Int Congress on Drug
Therapy in HIV Infection
|
-
Protease inhibitor-based antiretroviral therapy switch to
efavirenz-based regimens
P Khaykin, S Staszewski, B Dauer, et al
Abstract
-
Similar virologic and immunologic response to efavirenz or
lopinavir/ritonavir-based HAART in a
large cohort ofantiretroviral-naïve patients with advanced HIV
infection
F Pulido, J Arribas, S Moreno, et al
Abstract
-
Efavirenz (EFV) vs. Lopinavit/ritonavir (LPV/r)-based combined
antiretroviral therapy in antiretroviral-
nave HIV-infected patients from the Spanish VACH cohort: the SUSKA
study
P Domingo, R Teira, I Suarez-Lozano, et al
Abstract
-
Simplification from protease inhibitor (PI) to efavirenz (EFV) based
HAART in virologically suppressed
HIV-infected subjects
C Cohen, E DeJesus, R Campo, et al
Abstract-
Pharmacogenetic factors associated to virological failure and/or CNS
toxicity in patients treated
with efavirenz
S Rodriguez-Novoa, P Barreiro, C de Mendoza, et al
Abstract
-
Similar antiviral efficacy and tolerability between efavirenz and
lopinavir/ritonavir, administered
with abacavir/lamivudine (Kivexa), in naive patients: a multicentre,
randomized study
P Echeverria, G Carosi, J Galves, et al
Abstract-
High efavirenz trough concentrations (ETC) and CNS toxicity are
associated with CYP2B6
single nucleotide polymorphisms (SNPs) in black Africans
S Andrews, S Fredericks, Y Jamshdi, et al
Abstract-
TDM of efavirenz as a tool of adherence in HIV-infected children
R Rosso, A Di Biagio, C Dentone, et al
Abstract
-
Simplification to efavirenz + abacavir/lamivudine (Kivexa) in
previously suppressed HIV-infected
patients compared with other conventional regimens of 2 nucleosides +
efavirenz: 6-months of follow-up
P Echeverria, J de la Torre, J Pasquau,
et al
Abstract
-
Exploring the feasibility of dried blood spots for quantification of
lopinavir, nevirapine and efavirenz
concentrations
L Else, L Dickinson, M Schellenberger, et al
Abstract
XVI International
AIDS Conference
|
-
Efavirenz
during the second half of pregnancy is safe for infants of HIV -infected women
J.A. Collins, M.
Allauja,
M. Castromonte
Abstract
-
EFV
as initial antiretroviral therapy is effective in patients with an advanced
HIV-1 infection regardless
to baseline CD4 counts
J. Romo-Garcia
Abstract
-
Meta-analysis of efavirenz-based therapy in advanced HIV disease
R.M. Plank, S.
Eapen, M.L. Pisculli, P.E. Sax
Abstract
-
Early antiretroviral treatment-related adverse events in mineworkers commencing
efavirenz-
containing regimens in South Africa
J. Whetham, S. Charalambous, J. Lewis,
et al
Abstract
-
Concomitant treatment with efavirenz and Rifampicin doesn´t require dose
modifications for the expected
clinical, virologic and inmunologic response to antiretrovirals in AIDS patients
with tuberculosis
Carcamo Estrada M.d.R., Samayoa J., Mejìa C.
Abstract
-
Efavirenz used in HIV-patients with underlying liver disease: No different
increasing rates of gGT- and
ALT-values compared to liver-healthy HIV-patients with continuous TDM of EFV-plasma levels
Katsounas A., Frank A., Winzer R., et al
Abstract
-
Racial
differences in self-reported adherence and association with virologic failure on
efavirenz (EFV)-
containing regimens for initial HIV therapy: results from ACTG A5095
Schackman B., Ribaudo H., Krambrink A., et al
Abstract
-
Bioequivalence of the co-formulation of efavirenz /emtricitabine/tenofovir DF
Mathias A., Plummer A., Skillington J., et al
Abstract.
-
The ARK
EFV-test (TM): a rapid, automated immunoassay for therapeutic drug, monitoring
of
efavirenz
Helms M., Holland D., Espina-Quinto R., et a l
Abstract
-
Comparison of the changes in high density cholesterol (HDL) among efavirenz
(EFV) and atazanavir
(TAZ)
users and characterization of factors associated with this change
Ganesan A., Mccarthy S., Furtek K., et al
Abstract
-
Efficacy and safety of nevirapine versus efavirenz when combined in ART regimens
in HIV-infected
antiretroviral-naïve persons (the NNRTI substudy of FIRST-CPCRA 058)
van den Berg-Wolf M., Peng G., Xiang Y, et al
Abstract
-
Interactions between efavirenz and cellular efflux transporters
Chandler B., Holmes B., Janneh O., et al
Abstract
-
I
mpact
of race on efficacy and the occurrence of nervous system symptoms (NSS) in
HIV-Infected
patients following simplification from a twice-daily or more Frequent HAART
regimen to a once-daily
efavirenz (EFV)-based HAART regimen
Sension M., Jayaweera D., Lackey P., et al
Abstract
-
Boosted-atazanavir versus efavirenz: a retrospective review of two common once a
day regimens in
treatment-naïve patients from a large county clinic in Houston
Andrade R., Cartin-Ceba R., Zerai T., et al
Abstract
-
Overview of time to loss of virologic response (TLOVR) outcomes between
efavirenz-based regimens
in
ART-naive HIV-1-infected adults
Bartlett J.A., Chen S.-S., Quinn J.B., Wulfsohn M.
Abstract
-
Calculated creatinine clearance (CrCl) with two efavirenz (EFV)-based regimens
in naïve patients:
tenofovir (TFV)/didanosine (ddI) vs ddI/lamivudine (3TC )
Waters L., Maitland D., Moyle G., et al
Abstract
-
Immune
restoration syndrome (IRS) as a surrogate marker for immunologic response to
generic,
nevirapine-based V.S. to efavirenz- based antiretroviral regimens
Putcharoen O., Suankratay C., Tantawichien T, et al
Abstract
-
Pregnancy outcome in women exposed to efavirenz
Joao E.C., Calvet G.A., Cunha C.B., et al
Abstract -
DEXA
outcomes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz
or both plus
dual
nucleosides: long-term results from A5005s, a substudy of ACTG 384
Dubé M., Komarow L., Mulligan K., et al
Abstract
-
Liver
toxicity of efavirenz (EFV) and lopinavir/ritonavir (LPV/r) based regimens as
first-line therapy
in the
clinical practice
Perez-Elias M.J., Moreno A., et al
Abstract
-
Simplification to a once-daily efavirenz (EFV)-based HAART regimen from a
twice-daily or more
frequent HAART regimen maintains virologic suppression at 48 weeks
Boyle B., Morales Ramirez J., Brand D., et al
Abstract
-
Efavirenz during the second half of pregnancy is safe for infants of HIV
-infected women
Collins J.A., Allauja M., Castromonte M.
Abstract
-
Quantification of intracellular efavirenz in HIV-1-infected patients by LC-MS/MS
S. Kato, R. Tanaka, H. Hanabusa, et al.
Abstract
-
Differences in
Calculated Glomerular
Filtration Rates in
Efavirenz- or
Tenofovir-treated Adults
in
ESS40006
M
Thompson, R Haubrich D
Margolis, et al
Abstract-
Metabolic Analyses within
A5095: Effect of Efavirenz
against an
All-nucleoside/Nucleotide
Background
C Shikuma, Y
Yang, W Meyer, et al
Abstract-
CYP2B6-G516T
Polymorphisms Influence
Plasma Concentrations of
Efavirenz in HIV-
1-infected Children
Receiving HAART
A Saitoh, C
Fletcher, R Brundage, et al
Abstract-
TREC Response in P1021: A
Once-daily Regimen of
Emtricitabine, Didanosine, and
Efavirenz
in Previously Naive Children
R
Dickover, D Smith, P Britto, et
al
Abstract-
Replicative Capacity Effect of
Mutations that Are Associated with
Efavirenz Hypersusceptibility
N Shulman, J Mellors,
S Clark, et al
Abstract-
POSTER
T215F Mutation and Abacavir or Efavirenz
Use Are Linked to the L74I Mutation
Selection
M Wirden, A G Marcelin, J
Ghosn, et al
PDF Poster
Abstract
-
The Steady-state Pharmacokinetics of Efavirenz and
Lopinavir/Ritonavir in HIV-infected Persons
Requiring Hemodialysis: AIDS Clinical Trials Group Study A5177
S Gupta, S
Rosenkranz, Y Segal, et al
Abstract-
POSTER
Genetic Variability of CYP2B6 in
Individuals with Extremely High Efavirenz Plasma
Concentrations
M Rotger, S Colombo, M Cavassini,
et al
PDF Poster
Abstract
-
Multilocus Gene-Gene
Interactions May Predict Efavirenz Pharmacokinetics
and Treatment Response:
Analysis NWCS 213 of ACTG
Study 384
A Motsinger, M Ritchie,
R Shafer, et al
Abstract-
Evaluation of Efavirenz Transport by P-glycoprotein and
Uptake Transporters
C Marzolini, B Leake, U
Schwarz, et al
Abstract-
POSTER
Quality of Life and Depression among HIV+
Patients, Receiving Efavirenz- or
Protease Inhibitor-based HAART in Dakar, Senegal
M
Poupard, N Ngome Gueye, D Thiam, et al
PDF Poster
Abstract
-
Randomized Intensification of a Triple Nucleoside Regimen with
Efavirenz or Tenofovir in ACTG 5095
R Gulick, C
Lalama, C Shikum, et al
Abstract-
Viral Decay Rates in Men and Women
Receiving Triple-nucleoside or Efavirenz-containing ART:
Viral Dynamics Substudy of ACTG A5095
K Squires,
H Ribaudo, D Kuritzkes, et al
Abstract-
Long-term Neuropsychological Effects of Efavirenz-based
Treatment
D Clifford,
S Evans, Y Yang, et al
Abstract-
POSTER
A 2-Way
Pharmacokinetic Interaction between
Efavirenz and Carbamazepine
S Kaul, P Ji, J
Xie, F Johnson, et al
1
PDF Poster
Abstract
|
Annan T., Mandalia S., Bower M., et al
Abstract
POSTER
Impact of Race on the Efficacy and
Occurrence of Nervous System Symptoms
in
HIV-Infected Subjects Following a Switch from Protease Inhibitor to an
Efavirenz-Based
Regimen
DeJesus E ,Espinoza L. Sension M, et al
PDF Poster
Compared hepatotoxicity of the two available non-nucleoside
reverse transcriptase
inhibitors in a cohort of HIV-infected patients naïve to
either efavirenz or nevirapine
Manfredi R., Calza L., Chiodo F.
Abstract
Can efavirenz be taken in the morning?
Skeie L., Maeland A.
Abstract
Impact of Race on the Efficacy and Occurrence of Nervous
System Symptoms (NSS) in
HIV-infected Subjects Following a Switch from a Protease
Inhibitor (PI) to an Efavirenz
(EFV)-based Regimen
DeJesus E., Espinoza L., Sension M., et al
Abstract
Efavirenz And Didanosine Associated With Lamivudine Or
Tenofovir As Once-Daily Therapy
In Clinical Practice.
Knobel H., Arazo P., Teira R., et al
Abstract
Clinical and virological outcomes following switch from a
first protease inhibitor (PI) containing
HAART to a three- (TDR) or four-drug regimen (FDR) with
either efavirenz (EFV) or nevirapine
(NVP) and/or abacavir (ABC).
Abgrall S., Yeni P., Bouchaud O., Costagliola D.
Abstract
Effects of Efavirenz (EFV) and Lopinavir/ritonavir (LPV/r)
as First-line Therapies on lipid profile
Perez Elias M.J., Moreno A., Moreno S., et al
Abstract
Efavirenz plasma concentration is predictive of virologic
success in a cohort of HIV-1-infected
patients treated in Libreville, Gabon.
Clevenbergh P., Okome-Nkoumou M., Descamps D., et al
Abstract
Comparative Analysis of the Clinical, Immunological and
Virological Outcomes of
Initial HAART based on Efavirenz or Ritonavir/Lopinavir in
the Clinical Setting.
Moreno A., Perez-Elias M.J., Lopez D., et al
Abstract
Risk of liver toxicity in HCV/HIV coinfected patients with
advanced chronic liver disease or
cirrhosis receiving nevirapine, efavirenz or lopinavir/r
Casado J., Aranzabal L., Moya J., et al
Abstract
6th
International Workshop on Clinical
Pharmacology
of HIV Therapy |
|
Efavirenz
Main Page
Main
New/Newsworthy
